Updates on capivasertib, belzutifan, talquetamab, & durvalumab
Jun 18, 2026 - 00:19:32
Radio and PodcastLive Radio & PodcastsScience & Medicine
BCL2 & HER2 Targeting Agent Updates
The FDA has been a bunch of busy bees with new approvals: 1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell Lymphoma 2. An all PO regimen of decitabine/cedazuridine + venetoclax is approved...
About This Episode
BCL2 & HER2 Targeting Agent Updates is an episode from OncoPharm by OncoPharmPod. The FDA has been a bunch of busy bees with new approvals: 1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell Lymphoma 2. An all...
Podcast
This episode belongs to OncoPharm.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published May 21, 2026, 00:13:45 long, audio available.
Related Episodes
Continue listening to more episodes from OncoPharm.
Asco '26
Jun 11, 2026 - 00:25:38
Pivekimab sunirine
May 28, 2026 - 00:13:49
IMHOTEP, PJP, and more
May 14, 2026 - 00:09:59
Vepdegestrant
May 7, 2026 - 00:11:35
Targets Trop 2
Apr 30, 2026 - 00:12:41
Promising Pancreatic Cancer Data
Apr 23, 2026 - 00:13:56
ICI-Induced T1DM
Apr 16, 2026 - 00:13:24